Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space

NetworkNewsWire Editorial Coverage

News provided by

Aug 03, 2021, 08:30 ET

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- One of the most pervasive diseases in first-world countries, heart disease is the leading cause of death for men and women of most racial and ethnic groups in the United States, with one person dying every 36 seconds from cardiovascular disease. According to the Centers for Disease Control and Prevention (CDC), high blood pressure, or hypertension, is a key risk factor for both heart disease and stroke, and nearly half of all adults in the United States, or 108 million, have hypertension — yet only about 24% of those have their condition under control. Many don't even know they have it. The urgency of finding effective treatments for this life-threatening disease can't be understated, with many companies, including Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its patented DehydraTECH(TM) drug delivery, joining the effort to offer safe, effective and affordable treatments. Hypertension and related conditions are also points of focus for other drug-making juggernauts such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), Novartis AG (NYSE: NVS) and AstraZeneca PLC (NASDAQ: AZN).

High blood pressure is a life-threatening disease that can be managed with effective treatment.
Lexaria is a first mover in developing potential treatment base on its DehydraTECH technology.
The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.
Recent human clinical study using DehydraTECH technology demonstrated rapid, sustained drop in blood pressure along with excellent tolerability.

Click here to view the custom infographic of the Lexaria Bioscience editorial.

Hypertension Running Wild

Controlling blood pressure is essential to health. High blood pressure is a primary or contributing cause of death in almost 500,000 deaths a year, and hypertension can double the risk of a heart attack and quadruple the chance of having a stroke, plus raise the likelihood of heart failure, vision loss, renal disease, dementia, peripheral artery disease, and more. And it's not just an "old-person" problem; nearly one in four adults aged 20 to 44 have high blood pressure. In addition, high blood pressure costs the United States about $131 billion each year.

The good news? The disease can be managed — and even cured — with effective treatment. With that in mind, it's no surprise that the global anti-hypertensive drugs market is expected to grow from $24.17 billion in 2020 to $27.81 billion in 2025. Even with current hypertension drugs available, only 24% of the 108 million people in the U.S. with high blood pressure have their condition under control. It's a market ripe for innovation.

Increasing Onset, Bioavailability, Potency

Lexaria Bioscience Corp. (NASDAQ: LEXX) may be on the forefront of some of the exciting innovation in the space. The Kelowna, British Columbia-based company has developed and patented its DehydraTECH technology, a drug-delivery platform for increasing the speed of onset, bioavailability and drug potency. The mechanics involve combining an active pharmaceutical ingredient (API) with fatty acid oil and then applying the mix to carrier particles, which can even be common ingredients such as tapioca starch or gum arabic. Next, a patented dehydration synthesis procedure is performed, and the product is rendered as powder or liquid for use in the desired final form factor, such as a pill, tablet, chewable or oil.

Lexaria has been working with National Research Council of Canada, the biggest R&D organization in the country, since 2017 on defining the qualities of DehydraTECH. Among other things, Nuclear Magnetic Resonance molecular characterization suggests DehydraTECH does not change the chemical structure of an API it delivers, which is critical in reliance on original API safety data in developing novel delivery methods without starting from scratch regarding the FDA process. This keeps the door open to a faster path to market.

Ultimately what this means is DehydraTECH could make lower doses of some substances more effective while even reducing side effects. The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.

Early Results Show Extreme Promise

Just last month, Lexaria announced that a human clinical study using DehydraTECH technology demonstrated a rapid and sustained drop in blood pressure along with excellent tolerability. "We are very encouraged by these early results in our 2021 hypertension program," said Lexaria CEO Chris Bunka. "Lexaria's technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in stage 2 hypertensive volunteers."

Initial results show that blood pressure was reduced across both male and female volunteers and was most pronounced in the first 10–50 minutes of the study treatment, reinforcing pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic controls. Dr. Phil Ainslie, the lead investigator on the study, commented that "these early results are extremely promising in this at-risk hypertensive population and provide a fundamental support for expansion into more prolonged repeat dosing and future longer term clinical trials.

Platform Diversification

Lexaria's vision and focus is on several core business segments for DehydraTECH, including heart disease and hypertension, reduced-risk noncombusted nicotine and improved antiviral drug delivery, to name a few. Multiple successes on different fronts have been reported recently, including work in the antiviral program where DehydraTECH has been used to process compounds from leading drugs used for antiviral drugs for SARS-CoV-2/COVID-19 and HIV/AIDS. This is critical work not only for hopefully treating COVID-19 today but also in order to be better prepared when the next pandemic inevitably comes (think bird flu, swine flu, MERS, SARS, etc.).

The scalability to address a diverse group of market opportunities lends color to the potential of DehydraTECH. Consider the antivirals market that is in the spotlight right now because of the COVID-19 pandemic and the circulating delta variant is estimated at $52.1 billion and forecast to reach $66.7 billion by 2025. But DehydraTECH is so versatile, there are many other potential applications. Lexaria sees opportunities in human hormones (e.g., testosterone and estrogen replacement, a $21.9 billion market); oral mucosal nicotine (global smokeless tobacco products market valued at $13.6 billion in 2018), vitamin D3 ($1.1 billion market); PDE5 inhibitors ($4.4 billion market in 2014); and non-steroidal anti-inflammatories ($15.6 billion market in 2019).

Cardiovascular Disease Market Only Getting Bigger

Lexaria is only tapping into a slice of the $92.4 billion cardiovascular drug market that generates billions of dollars in profits every year for drug makers. Majors dominate this lucrative market expected to rise to $107.77 billion in 2025, fueled by a return to normal healthcare practices in a post-pandemic economy.

Pfizer Inc. (NYSE: PFE), one of the largest pharmaceutical companies in the world, notes that despite advances in care and treatment, cardiovascular disease (CVD) remains the number-one cause of death worldwide, with the prevalence only expected to increase. Pfizer is committed to harnessing its legacy and expertise as it aims to address gaps in CVD treatment through the development of new medicines that can meaningfully reduce CV risk for patients. Originally manufactured by Pfizer, NORVASC(R) has been available for more than 25 years and is prescribed to treat high blood pressure (hypertension), certain types of chest pain (angina), and blocked arteries of the heart (coronary artery disease).

Merck & Company Inc. (NYSE: MRK) announced earlier this year that the FDA had granted approval to its (and Germany-based partner Bayer's) heart-failure drug, Verquvo (vericiguat). The company noted that patients with symptomatic chronic heart failure and reduced ejection fraction have a high risk for hospitalization after experiencing symptoms of heart failure requiring outpatient IV diuretic treatment or hospitalization. Many of those, perhaps even more than half, are hospitalized within a month of discharge due to a worsening event, and approximately one in five dice within two years. The approval of VERQUVO provides doctors, health-care professionals, and patients with a new option to current available therapies.

Novartis AG (NYSE: NVS), like most other majors, is highly diversified, with its top-20 products generating $16 billion in sales during the first half of 2021. Entresto, its drug to reduce the risk of cardiovascular death and hospitalization for heart failure in certain patients, was its biggest gainer during Q2, with sales surging 53% from the year prior quarter to $886 million during the quarter. Novartis is committed to reimagining medicine and using innovative science and technology to address some of society's most challenging healthcare issues.

AstraZeneca PLC (NASDAQ: AZN) announced in April that its proprietary sodium-glucose cotransporter 2 (SGLT2) inhibitor, Farxiga, has been approved for use in the United States. In phase 3 trials, the drug demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death. Chronic kidney disease is often associated with a heightened risk of heart disease or stroke, and the company called the approval of Farxiga, one of the most significant advancements in the treatment of chronic kidney disease in more than 20 years.

Heart disease is the most indiscriminate killer in the United States. Every year it is a leading cause of death for men, women and people of most racial and ethnic groups. About one in every four deaths is caused by heart disease, equating to roughly 655,000 Americans each year. It's clear that drug sales are booming trying to combat it, but any innovation to make these medicines (many of which have ugly side effects) better will almost certainly be welcomed with open arms.

For more information about Lexaria Bioscience Corp., please visit Lexaria Bioscience Corp.

About NetworkNewsWire

NetworkNewsWire ("NNW") is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork ("IBN"), that provides: (1) access to a network of wire solutions via NetworkWire to reach all target markets, industries, and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information, please visit: https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.

NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
Office Tel: 212.418.1217
[email protected]

Media Contact:
FN Media Group, LLC
[email protected]
+1-(954)345-0611 